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Impaired BKCa channel function 
in native vascular smooth muscle 
from humans with type 2 diabetes
Madeline Nieves-Cintrón1, Arsalan U. Syed1, Olivia R. Buonarati1, Robert R. Rigor1, Matthew 
A. Nystoriak2, Debapriya Ghosh1, Kent C. Sasse3, Sean M. Ward4, Luis F. Santana5, Johannes 
W. Hell1 & Manuel F. Navedo  1
Large-conductance Ca2+-activated potassium (BKCa) channels are key determinants of vascular smooth 
muscle excitability. Impaired BKCa channel function through remodeling of BKCa β1 expression and 
function contributes to vascular complications in animal models of diabetes. Yet, whether similar 
alterations occur in native vascular smooth muscle from humans with type 2 diabetes is unclear. 
In this study, we evaluated BKCa function in vascular smooth muscle from small resistance adipose 
arteries of non-diabetic and clinically diagnosed type 2 diabetic patients. We found that BKCa channel 
activity opposes pressure-induced constriction in human small resistance adipose arteries, and this is 
compromised in arteries from diabetic patients. Consistent with impairment of BKCa channel function, 
the amplitude and frequency of spontaneous BKCa currents, but not Ca2+ sparks were lower in cells from 
diabetic patients. BKCa channels in diabetic cells exhibited reduced Ca2+ sensitivity, single-channel open 
probability and tamoxifen sensitivity. These effects were associated with decreased functional coupling 
between BKCa α and β1 subunits, but no change in total protein abundance. Overall, results suggest 
impairment in BKCa channel function in vascular smooth muscle from diabetic patients through unique 
mechanisms, which may contribute to vascular complications in humans with type 2 diabetes.
The World Health Organization estimates that ~350 million people worldwide have non-insulin-dependent 
type 2 diabetes, a number that is expected to double by 20301. Vascular complications (e.g. hypertension, coro-
nary heart disease, stroke) are among the most prominent causes of morbidity and mortality in type 2 diabetic 
patients1–3. While endothelial dysfunction has long been recognized as a key link in the pathogenesis of vascu-
lar complications during diabetes, emerging data in human and animal models also implicate vascular smooth 
muscle dysfunction in this process3–11. At present however, there is limited information about the mechanisms 
underlying changes in vascular smooth muscle function in native cells from type 2 diabetic patients.
The contractile state of vascular smooth muscle in small resistance arteries is controlled by multiple ion chan-
nels12. Among them, large-conductance Ca2+-activated potassium (BKCa) channels play a key role in control of 
vascular smooth muscle contractility via tonic regulation of membrane potential13. Physiologically, these channels 
are activated by membrane depolarization and localized Ca2+ release events through ryanodine receptors (e.g. 
Ca2+ sparks) located in the sarcoplasmic reticulum13–15. The opening of BKCa channels by Ca2+ sparks results in 
the occurrence of BKCa-mediated spontaneous transient outward currents (STOCs), leading to vascular smooth 
muscle hyperpolarization and consequently vasodilation. Conversely, their inhibition causes membrane potential 
depolarization and vasoconstriction. BKCa channels are composed of four pore-forming α subunits in associa-
tion with accessory β subunits16. Four distinct BKCa β subunits (β1-β4) have been identified, with BKCa β1 being 
predominantly expressed in vascular smooth muscle16. The BKCa β1 subunit regulates BKCa channel activity by 
modulating its apparent Ca2+ sensitivity as well as its biophysical properties17. Impairment in BKCa β1 expres-
sion and function has been implicated in aberrant vascular BKCa channel activity in animal models of diabetes 
and hypertension, and in immortalized cell lines from human diabetic subjects9,18–25. However, whether similar 
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alterations in BKCa channel activity occur in native, freshly dissociated vascular smooth muscle cells from humans 
with type 2 diabetes has not been established.
Here, we investigated BKCa channel function in freshly isolated, small resistance adipose arteries and cor-
responding native vascular smooth muscle cells from obese non-diabetic and clinically diagnosed type 2 dia-
betic patients. Data revealed a reduction in iberiotoxin (IbTx) sensitivity of intact arteries from diabetic patients. 
This was associated with impaired BKCa channel activity due to decreased BKCa β1 function in diabetic vascular 
smooth muscle cells. In contrast to results observed in animal models9,21–23,25, impaired BKCa β1 function was not 
due to changes in BKCa β1 abundance, but to a reduced functional association between BKCa α and β1 subunits in 
diabetic cells. Thus, results suggest a mechanism for altered vascular BKCa channel function in patients with type 2 
diabetes with similar, but not identical features to those observed in animal models of diabetes.
Results
To establish whether BKCa channel function is impaired in native vascular smooth muscle cells during type 2 
diabetes, small diameter arteries were dissected from adipose tissue obtained from obese non-diabetic and clini-
cally diagnosed type 2 diabetic patients undergoing surgical sleeve gastrectomy (see Methods section). Available 
patient information is included in Supplementary Table S1.
Decreased IBTx sensitivity in arteries from diabetic subjects. Small diameter adipose arteries (aver-
age passive diameter between 50–90 μm; see Fig. 1A) from non-diabetic and clinically diagnosed diabetic patients 
were pressurized to 80 mmHg, and allowed to develop stable myogenic tone. Mean basal myogenic tone was 
44 ± 9% in non-diabetic arteries, and was modestly, although not significantly, elevated to 49 ± 3% in arteries 
from diabetic patients (P = 0.325). To assess the contribution of BKCa channels to vascular function, adipose arter-
ies from non-diabetic and diabetic patients were challenged with the selective BKCa channel inhibitor iberiotoxin 
Figure 1. Adipose arteries from diabetic subjects exhibit blunted response to IBTx. (A) Exemplary image of 
small resistance adipose arteries used in this study. The image below shows an expanded view of the area in 
the green square. (B) Representative diameter recordings of pressurized (80 mmHg) adipose arteries from 
non-diabetic and diabetic patients before and after perfusion of 100 nM iberiotoxin or a Ca2+ free + nifedipine 
(1 μM) solution. (C) Summary of iberiotoxin-induced constriction in non-diabetic (n = 7 arteries, 4 subjects) 
and diabetic (n = 5 arteries, 5 subjects) adipose arteries pressurized to 80 mmHg. (D) Scatter/bar plot 
summarizing vascular tone at 80 mmHg in response to 60 mM extracellular K+ in non-diabetic (n = 8 arteries, 
4 subjects) and diabetic (n = 6 arteries, 5 subjects) adipose arteries. *P < 0.05, Mann-Whitney test. Significance 
was compared between non-diabetic and diabetic datasets.
www.nature.com/scientificreports/
3SCientifiC REPORtS | 7: 14058  | DOI:10.1038/s41598-017-14565-9
(IBTx; 100 nM). IBTx caused robust vasoconstriction in non-diabetic arteries (24% decrease in diameter) (Fig. 1B 
and C; Supplementary Table S2). This is consistent with BKCa channel activity opposing vasoconstriction. In 
contrast, IBTx had little effect on pressurized adipose arteries from diabetic patients (4% decrease in diameter; 
Fig. 1B and C; Supplementary Table S2; P < 0.05). Arteries from both groups responded to external application 
of a 60 mM K+ solution with robust constriction (Fig. 1D; Supplementary Table S2), suggesting that differences 
in the IBTx response were not simply due to the inability of diabetic arteries to respond to a contractile stimulus. 
This decrease in IBTx sensitivity in diabetic arteries suggests impairment in BKCa channel function in arteries 
from diabetic patients.
Decreased STOC amplitude and frequency in vascular smooth muscle from diabetic 
patients. BKCa-mediated STOCs were recorded at membrane potential ranging from −60 mV to −10 mV. 
Figure 2A displays representative STOCs recordings from freshly dissociated vascular smooth muscle obtained 
from small diameter adipose arteries from non-diabetic and diabetic patients at −40 mV. STOCs amplitude and 
frequency increased with membrane depolarization in cells of both groups. However, a significant reduction 
in STOC amplitude was evident at several membrane potentials examined in cells from diabetic compared to 
non-diabetic patients (Fig. 2A and B). The slope of the STOC amplitude-voltage relationship was significantly 
smaller in diabetic (0.27 ± 0.01 pA/mV) compared to non-diabetic cells (0.38 ± 0.02 pA/mV; P < 0.05; F test) 
(Fig. 1B). STOC frequency was also significantly decreased in diabetic vascular smooth muscle cells at voltages 
from −30 to −10 mV (Fig. 1C; P < 0.05). The voltage dependency of STOC frequency was shifted toward more 
depolarized potentials in diabetic cells (V50 = −4 ± 4 mV) compared to non-diabetic cells (V50 = −21 ± 7 mV; 
Fig. 2C). These results suggest that BKCa channel activity is altered in vascular smooth muscle from diabetic 
patients.
Ca2+ spark activity is similar in vascular smooth muscle from non-diabetic and diabetic 
patients. STOC activity in vascular smooth muscle is tightly coupled to Ca2+ sparks13,15,26. These events were 
recorded from non-diabetic and diabetic vascular smooth muscle loaded with the fluorescent Ca2+ indicator 
fluo-4 AM to evaluate whether changes in Ca2+ spark activity could account for impairment in BKCa channel 
function in vascular smooth muscle from diabetic patients (Fig. 3A). Figure 3B and C shows that the amplitude 
and frequency of Ca2+ sparks were similar in non-diabetic and diabetic cells. These results suggest that impaired 
Figure 2. STOCs amplitude and frequency are reduced in vascular smooth muscle from diabetic patients. (A) 
Representative traces of spontaneous whole-cell BKCa currents (e.g. STOCs) at −40 mV in vascular smooth 
muscle from non-diabetic and diabetic patients. (B,C) Voltage dependency of STOC amplitude (B) and 
frequency (C) in cells from non-diabetic (n = 10 cells, 4 subjects) and diabetic (n = 13 cells, 4 subjects) patients. 
Solid lines represent the best fit of the amplitude data using a linear regression function and of the frequency 
data using a Boltzmann sigmoidal function. *P < 0.05, unpaired t test. Significance was compared between 
corresponding non-diabetic and diabetic datasets.
www.nature.com/scientificreports/
4SCientifiC REPORtS | 7: 14058  | DOI:10.1038/s41598-017-14565-9
BKCa channel function is not due to changes in Ca2+ spark activity in vascular smooth muscle from diabetic 
patients.
Impaired BKCa activity in vascular smooth muscle from diabetic patients. Single BKCa currents 
were recorded in excised membrane patches to evaluate whether differences in the functional properties of BKCa 
channels account for compromised channel activity during diabetes. BKCa currents were monitored at a physio-
logical membrane potential (−40 mV) with bath solution containing either 1 μM or 10 μM free Ca2+. Increasing 
free Ca2+ from 1 μM to 10 μM augmented the open probability (Po) of BKCa channels in both non-diabetic and 
diabetic cells (Fig. 4A and B). However, BKCa channel Po was significantly lower in diabetic cells compared to 
non-diabetic cells at each Ca2+ concentration tested (Fig. 4A and B). In addition, open time histograms revealed 
a shift toward shorter openings in diabetic cells (Fig. 4C; P < 0.05; F test). These results suggest a reduction in 
apparent Ca2+ sensitivity and dwell open time of BKCa channels in vascular smooth muscle cells from diabetic 
patients.
Figure 3. The frequency and amplitude of Ca2+ sparks is similar in non-diabetic and diabetic vascular smooth 
muscle. (A) Representative three-dimensional pseudo-color images of Ca2+ sparks (upper panels) and fractional 
fluorescence traces (F/F0; lower panels) from those sites in fluo-4 AM-loaded vascular smooth muscle cells from 
non-diabetic and diabetic patients. Scatter/bar plots summarizing Ca2+ spark amplitude (B) and frequency (C) 
in cells from non-diabetic (n = 254 events, 14 cells, 3 subjects) and diabetic (n = 333 events, 19 cells, 5 subjects) 
patients. *P < 0.05, Mann-Whitney test. Significance was compared between non-diabetic and diabetic datasets.
www.nature.com/scientificreports/
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Altered BKCa β1 subunit function in vascular smooth muscle from diabetic patients. The BKCa 
channel function is highly dependent on expression and function of the accessory BKCa β subunit17,27. To exam-
ine whether impaired BKCa channel activity in vascular smooth muscle from diabetic patients is due to changes 
in BKCa β subunit function, single BKCa currents were recorded in the absence or presence of tamoxifen (1 μM). 
This drug increases BKCa channel Po by engaging the BKCa β subunit as shown in Fig. 5A and B, and as previously 
reported by our group and others9,19,28. Whereas tamoxifen significantly increased the Po of BKCa in non-diabetic 
cells, it had a minimal effect in vascular smooth muscle from diabetic subjects (Fig. 5C and D). These results 
suggest that a reduction in BKCa β subunit function may contribute to impaired BKCa channel activity in vascular 
smooth muscle cells from diabetic patients.
Reduced association between BKCa α and BKCa β1 subunits in vascular smooth muscle from 
diabetic patients. To examine the molecular mechanisms underlying altered BKCa channel activity and BKCa 
β subunit function during diabetes, protein expression of the pore forming BKCa α subunit and BKCa β1 subunit 
were examined using Western blot analysis. Antibodies were validated for specificity using HEK293 cells express-
ing either BKCa α or BKCa β1 subunits (Fig. 6A and Supplementary Fig. S1). Bands of similar molecular weight for 
the BKCa α subunit were found in lysates from HEK293 cells stably expressing this subunit and human adipose 
arteries (Fig. 6A). The molecular weight of the BKCa β1 subunit was slightly higher in lysates from human adipose 
arteries compared to HEK293 cell transfected with a BKCa β1 construct (Fig. 6A), perhaps reflecting differences in 
post-translational modifications as recently observed29. A non-specific band of ~40 kDa was observed in lysates 
from HEK cells, but only cells expressing BKCa β1 showed the expected immunoreactive band at 25 kDa (Fig. 6A 
and Supplementary Figs S1A and S2A). Also note that only one immunoreactive band of expected molecu-
lar weight for the BKCa β1 was detected in human adipose arterial lysates (Supplementary Figs S1B and S2A). 
Figure 4. Decreased BKCa channel activity in vascular smooth muscle from diabetic patients. (A) 
Representative single BKCa channel traces at −40 mV from excised membrane patches of isolated human non-
diabetic and diabetic vascular smooth muscle cells in the presence of 1 μM and 10 μM free Ca2+ bath solution 
(C: closed; O: open). (B) Scatter/bar plot summarizing BKCa channel open probability (Po) at the indicated free 
Ca2+ concentration from human non-diabetic (n = 18 cells, 9 subjects) and diabetic (n = 27 cells, 15 subjects) 
cells. *P < 0.05, Mann-Whitney test. (C) Open dwell time histograms of BKCa channels in non-diabetic and 
diabetic vascular smooth muscle. The goodness of the fit was assessed with R2 and the F test was used for 
comparison between open time fits. Significance was compared between non-diabetic and diabetic datasets.
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Subsequent examination of total protein abundance for BKCa α and BKCa β1 subunits in human non-diabetic and 
diabetic arteries revealed no differences between groups (Fig. 6B and C).
To further explore mechanisms that may contribute to compromised BKCa channel activity and BKCa β1 sub-
unit function during diabetes, the coupling between BKCa α and BKCa β1 was examined using Proximity Ligation 
Assay (PLA)30 and immunofluorescence analysis. PLA fluorescent puncta are generated when proteins of interest 
are 40 nm or less apart. PLA signals were negligible when primary antibodies for BKCa α and/or BKCa β1 subunits 
were omitted from the preparation (Fig. 7A,B,C and H). As a positive control, vascular smooth muscle from 
non-diabetic and diabetic subjects stained with two different BKCa α subunit antibodies demonstrated robust PLA 
signals with similar number of PLA puncta (Fig. 7D,E and H). In vascular smooth muscle co-labeled for BKCa 
α and BKCa β1, data revealed a significant reduction in PLA puncta in diabetic cells compared to non-diabetic 
cells (Fig. 7F,G and H). Immunofluorescence analysis showed strong BKCa α-associated immunofluorescence of 
similar intensity (normalized to cytosol) along the plasma membrane of non-diabetic (1.7 ± 0.1) and diabetic 
(1.6 ± 0.1) vascular smooth muscle (P = 0.460; Mann Whitney Test; Supplementary Fig. S3). Conversely, the 
intensity of the BKCa β1-associated fluorescence along the plasma membrane was markedly reduced in diabetic 
cells (0.8 ± 0.1) compared to non-diabetic cells (1.5 ± 0.1; P < 0.05; Mann Whitney Test; Supplementary Fig. S3). 
Altogether, these results suggest that BKCa β1-mediated regulation of BKCa channels may be compromised in 
vascular smooth muscle from adipose arteries of diabetic patients due to suppressed functional coupling between 
BKCa α and BKCa β1 subunits, rather than a reduction in cellular subunit abundance.
Figure 5. Impaired BKCa β1 subunit function in human diabetic vascular smooth muscle. (A) Representative 
single BKCa channel records at +40 mV and 1 μM free Ca2+ obtained from excised membrane patches of 
HEK293 cells expressing only BKCa α subunit or coexpressing BKCa α + BKCa β1 subunits in the absence and 
presence of tamoxifen (1 μM). (B) Bar plot summarizing the change in open probability (tamoxifen: control) for 
HEK293 cells expressing BKCa α (n = 11 cells) or BKCa α + BKCa β1 (n = 12 cells) subunits. *P < 0.05, unpaired 
t test C) Representative single BKCa channel traces recorded from excised membrane patches of vascular 
smooth muscle from non-diabetic and diabetic patients with 1 μM free Ca2+ in the bath before (−) and after 
(+) application of 1 μM tamoxifen. (D) Amalgamated data summarizing BKCa open probability in non-diabetic 
(n = 17 cells, 9 subjects) and diabetic (n = 19 cells, 8 subjects) cells in the presence or absence of tamoxifen. (C: 
closed; O: open) *P < 0.05, Wilcoxon test. Significance for Fig. 5B was compared between cells co-expressing 
BKCa α + BKCa β1 vs. BKCa α only. Significance for Fig. 5D was compared to corresponding - tamoxifen datasets.
www.nature.com/scientificreports/
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Discussion
In this study we report three major novel findings related to BKCa channels in native small diameter adipose 
arteries and vascular smooth muscle cells from non-diabetic and type 2 diabetic patients. First, BKCa channel 
activity acts to oppose pressure-induced constriction in isolated human resistance adipose arteries, but this is 
compromised in arteries from diabetic patients. Second, BKCa channel activity is impaired in vascular smooth 
muscle from diabetic patients, as reflected by reduced apparent Ca2+ sensitivity, dwell open time and BKCa β 
subunit function. Third, compromised BKCa β subunit function during diabetes is not associated with changes in 
total protein abundance of this subunit, but rather seems to be the result of a reduction in the association/cou-
pling between BKCa α and BKCa β1 subunits. The implications of these changes are significant as they may impact 
vascular reactivity and/or contribute to vascular complications in humans with type 2 diabetes, independent of 
changes in endothelial function6,24,31–33.
Figure 6. No change in BKCa subunit total protein levels in arterial lysates from non-diabetic and diabetic 
patients. (A) Representative immunoreactive bands corresponding to BKCa α1 and BKCa β1 subunits in lysates 
from untransfected HEK293 cells (HEK), HEK293 cells transfected with either BKCa α1 or BKCa β1 subunit 
and human arteries from non-diabetic patients (n = 3 lysates per condition). Full-length blots are shown in 
Supplementary Fig. S2A. (B) Representative immunoreactive bands corresponding to BKCa α1 and BKCa β1 
subunits, and β-actin as a normalization control. Full-length blots are shown in Supplementary Fig. S2B. (C) 
Corresponding densitometric summary data for each subunit obtained using arterial lysates from non-diabetic 
(n = 10 lysates) and diabetic (n = 10 lysates) patients. *P < 0.05, Mann-Whitney test. Significance was compared 
between non-diabetic and diabetic datasets.
www.nature.com/scientificreports/
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Results of experiments examining the effects of IbTx on arterial tone suggest that BKCa channels serve an 
important physiological role to oppose pressure-induced vasoconstriction in human adipose arteries, but become 
severely compromised in adipose arteries from diabetic patients (Fig. 1). These results suggest that BKCa channel 
function is compromised in adipose arteries from humans with diabetes. Consistent with this, BKCa-mediated 
STOCs amplitude and frequency as well as single BKCa channel function were significantly reduced in dissociated 
vascular smooth muscle from adipose arteries from diabetic subjects (Figs 2 and 4). Similar results were observed 
in a number of studies using vascular smooth muscle from several vascular beds and different animal models of 
diabetes9,21–23,25,34. A reduction in BKCa channel activity and BKCa β1 function may also contribute to vascular 
complications by aggravating vessel wall remodeling and fibrosis during diabetes35. Thus, a potential common 
BKCa-mediated mechanism contributing to vascular complications during diabetes may be engaged in a variety 
of species. In animal models of diabetes, alterations in BKCa channel function have been associated, in part, to 
changes in the activity of Ca2+ sparks21,22,25. Here, no changes in Ca2+ sparks properties were detected between 
dissociated vascular smooth muscle from adipose arteries from non-diabetic and diabetic patients (Fig. 3). These 
results are similar to those found in vascular smooth muscle from high fat diet mice in which Ca2+ spark activity 
was unaffected compared to cells from low fat fed mice9. Discrepancies with other studies could arise from exper-
imental conditions, use of smooth muscle from different vascular beds, or intrinsic differences between murine 
and human cells/tissue31,36. Regardless, our results implicate other mechanisms as culprit for comprised BKCa 
channel activity in human vascular smooth muscle during diabetes.
The accessory BKCa β1 subunit finely tunes the activity of BKCa channels in vascular smooth muscle by increas-
ing their voltage- and calcium-sensitivity27. Impaired BKCa channel function has been associated with suppression 
of BKCa β1 subunit function in several studies with animal models of diabetes9,21–23,25. Moreover, compromised 
BKCa channel activity was linked with suppression of BKCa β1 subunit function in human vascular smooth muscle 
from Han Chinese patients with hypertension24. We found that BKCa β1 subunit function was significantly sup-
pressed in diabetic vascular smooth muscle from adipose tissue as assessed by tamoxifen sensitivity (Figs 4 and 5). 
Note that consistent with experiments here (Fig. 5), several groups including ours have validated and confirmed 
that the effects of tamoxifen on BKCa channels require the presence of the BKCa β1 subunit9,19,28. The impairment 
in BKCa β1 subunit function helps explain the reduced apparent Ca2+ sensitivity and dwell open time of BKCa 
Figure 7. Decreased association between BKCa α1 and BKCa β1 subunits in vascular smooth muscle cells from 
diabetic patients. (A–C) Differential interference contrast (DIC) and confocal fluorescent PLA puncta (red) 
and DAPI (blue) images of freshly dissociated human vascular smooth muscle labeled with mouse-anti BKCa 
α1 (A), rabbit-anti BKCa α1 (B), and rabbit-anti BKCa β1 (C) antibodies. (D,E) DIC (left) and fluorescence PLA 
(red)/DAPI (blue) (right) images of dissociated vascular smooth muscle from non-diabetic (D) and diabetic 
(E) patients co-labeled with two distinct antibodies for the BKCa α1 subunit. (F,G) DIC (left) and fluorescence 
PLA (red)/DAPI (blue) (right) images of dissociated human vascular smooth muscle from non-diabetic (F) 
and diabetic (G) patients co-labeled for BKCa α1 and BKCa β1 subunits. Scale bar = 10 μm. (H) Quantification of 
PLA fluorescent puncta per μm2 cell area for non-diabetic and diabetic vascular smooth muscle cells labeled for 
mouse-anti BKCa α1 (n = 19 cells), rabbit-anti BKCa α1 (n = 27 cells), rabbit-anti BKCa β1 (n = 12 cells), mouse-
anti BKCa α1 + rabbit-anti BKCa α1 (n = 24 non-diabetic, 14 diabetic cells); mouse-anti BKCa α1 + rabbit-anti 
BKCa β1 (n = 27 non-diabetic, 24 diabetic cells). *P < 0.05, Mann-Whitney test. Significance for columns 1, 2, 3 
and 5 was compared to column 4, and column 7 was compared to column 6.
www.nature.com/scientificreports/
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channels as well as the blunted IBTx-induced constriction in diabetic compared to non-diabetic vascular smooth 
muscle cells/adipose arteries. The loss of BKCa β1 subunit function in animal models of diabetes9,21–23,25 and in 
humans with hypertension24 has been mainly attributed to transcriptional and/or post-translational changes in 
BKCa β1 subunit expression. In contrast with these seemingly consistent molecular mechanisms, no changes in 
total BKCa α and BKCa β1 protein levels were detected between non-diabetic and diabetic arterial lysates (Fig. 6). 
Rather, PLA data revealed a reduced association between BKCa α and BKCa β1 subunits in diabetic cells com-
pared to non-diabetic cells (Fig. 7). Furthermore, immunofluorescence imaging provided evidence of a decreased 
surface expression of BKCa β1, but not BKCa α, in diabetic cells compared to non-diabetic cells (Supplementary 
Fig. S2). This is important as recent studies have suggested that dynamic trafficking of the BKCa β1 subunit to the 
plasma membrane is essential for coupling with the mostly membrane bound, pore forming BKCa α subunit in 
vascular smooth muscle37,38. This dynamic interaction between BKCa subunits contributes to vascular reactivity 
under basal conditions37 and in response to chronic angiotensin II signaling38. Also note that a recent study using 
human vascular smooth muscle has shown that changes in KV1.5 surface expression (perhaps due to altered 
trafficking of the subunit) rather than differences in total protein levels has been associated with impaired KV1.5 
channel and vascular reactivity in humans with coronary artery disease39. Thus, it is tempting to speculate, for 
future studies, that a change in BKCa β1 subunit trafficking may contribute to compromised BKCa channel activity 
and vascular reactivity in humans with diabetes.
Vascular complications during diabetes may also be associated with impairment in the function of other ion 
channels in vascular smooth muscle. For example, it was recently reported that L-type Ca2+ channel (LTCC) 
activity was significantly augmented in vascular smooth muscle from humans with diabetes40. This can stimu-
late Ca2+ influx to increase global intracellular Ca2+ in vascular smooth muscle. Interestingly, use of a mathe-
matical model of rodent vascular smooth muscle electrophysiology and Ca2+ dynamics showed that increased 
LTCC activity predominantly contributes to impaired intracellular Ca2+ during diabetic hyperglycemia41. Yet, 
the model also revealed that this effect on global intracellular Ca2+ is substantially amplified when an increase 
in LTCC activity is accompanied by a decrease in the activity of potassium (K+) channels41. Indeed, previous 
studies have shown a selective suppression in voltage-gated K+ (KV) and BKCa channel activity that is associated 
with downregulation of KV2.1 and BKCa β1 subunit, respectively, in vascular smooth muscle from diabetic mice 
on a high fat diet9,10. Thus, potentiation of LTCC activation and suppression of K+ channel activity, including 
that of BKCa channels as in this study, may synergize to impact vascular reactivity and/or contribute to vascular 
complications in humans with diabetes. Given the role of KV channels in vascular smooth muscle excitability due 
to their influence on membrane potential, it will be important to examine the function of these channels as well 
as the individual contributions of different KV subunits in human cells during control conditions and in diabetes. 
Collectively, these data will critically inform the development of novel computational models specific to human 
vascular smooth muscle. This computational approach may help identify and predict the relative contribution of 
many elements (i.e. LTCC, KV channels, BKCa channels, etc.) that interact non-linearly to control vascular smooth 
muscle excitability in humans during physiological and pathological conditions.
The use of human tissue from obese non-diabetic and clinically diagnosed type 2 diabetic patients provides 
unparalleled translational significance. Yet, factors such as underlying environmental factors, biological variables 
such as sex and age, genetic background, disease progression, prescription history, personal habits (e.g. smok-
ing) and comorbidities may confound results. Despite these limitations, data in this study are internally con-
sistent and reproducible across different experimental approaches. Indeed, we also recently demonstrated high 
reproducibility in biochemical and electrophysiological outcomes using similar tissue samples40. Furthermore, 
whereas the use of tissue from obese non-diabetic patients is less than ideal as a true “control”, it does highlight the 
added stress imposed by diabetes in mediating alterations in BKCa channel activity. To conclude, and to the best 
of our knowledge, this study provides the first direct evidence that compromised BKCa channel activity in native, 
freshly dissociated vascular smooth muscle may contribute to vascular complications in type 2 diabetic patients. 
Interestingly, the mechanisms underlying aberrant vascular BKCa channel activity in humans with diabetes follow 
some, but not all, the molecular features observed in animal models of diabetes. Gathering information from 
native human cells may be necessary for development of rational strategies to treat vascular complications in 
humans with type 2 diabetes.
Methods
Human Tissue (Study Approval). Excised adipose arteries from obese patients undergoing surgical sleeve 
gastrectomy and that were either non-diabetic or clinically diagnosed with type 2 diabetes were used. Samples 
were obtained after Institutional Review Board (IRB) approval from the University of Nevada Reno School of 
Medicine (IRB ID: 2013-019) and in accordance with the guidelines of the Declaration of Helsinki. The need for 
informed consent was waived by IRBs at the University of Nevada Reno School of Medicine (IRB ID: 2013-019) 
and the University of California Davis School of Medicine (IRB ID: 597267-1) because the tissue is considered 
“waste”, has no codification that could be used to identify patients and was determined not to be human subject 
research in accordance with United States of America federal regulations, as defined by 45 CFR 46.102(f). This 
precludes the acquisition of detailed clinical profiles other than sex, age and whether the patient was diabetic 
or not (see Table S1). Therefore, no exclusions were made due to medication history or presence of comorbid-
ities. Patients were considered diabetic if they had a hemoglobin A-1c level equal to or greater than 6.5% on 
pre-surgical testing, or if they were on medication for diabetes treatment42. Collected tissue was placed in cold 
phosphate-buffered saline (PBS) solution containing (in mM): 138 NaCl, 3 KCl, 10 Na2HPO4, 2 NaH2PO4, 5 
D-glucose, 0.1 CaCl2, and 0.1 MgSO4, pH 7.4 with NaOH until used.
Vascular Smooth Muscle Cell Isolation. Single vascular smooth muscle cells were dissociated from small 
diameter adipose arteries from non-diabetic and type 2 diabetic patients using enzymatic digestion as previously 
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described40. Adipose arteries were dissected in ice-cold dissection buffer composed of (in mM): 140 NaCl, 5 KCl, 
2 MgCl2, 10 D-glucose, and 10 HEPES, pH 7.4 with NaOH. Following dissection, arteries were cut in small pieces 
and digested in dissection buffer supplemented with papain (26 U/ml) and dithiothreitol (1 mg/mL) at 37 °C for 
15 minutes. After this first incubation period, the solution was exchanged with dissection buffer supplemented 
with collagenase type H (1.95 U/mL), elastase (0.5 mg/mL) and soybean trypsin Inhibitor (1 mg/ml) at 37 °C for 
15 minutes. Cells were then washed in ice-cold dissection buffer three times. Glass pipettes of decreasing diame-
ters were then used to gently triturate arteries and obtain single vascular smooth muscle cells. Isolated cells were 
maintained in ice-cold dissection buffer until use.
Arterial Diameter Measurements. Freshly dissected small diameter adipose arteries were cannulated 
on glass micropipettes and mounted in a 5 mL myograph chamber (Living Systems Instrumentation, St. Albans, 
VT) as described previously9,43,44. The vessels were pressurized to 20 mmHg and allowed to equilibrate while 
continuously perfused (37 °C, 30 min, 3–5 mL/min) with physiological saline solution (PSS) consisting of (in 
mM): 119 NaCl, 4.7 KCl, 2 CaCl2, 24 NaHCO3, 1.2 KH2PO4, 1.2 MgSO4, 0.023 ethylenediaminetetraacetic acid 
(EDTA) and 10 D-glucose aerated with 5% CO2/95% O2, pH 7.35–7.40. Following an equilibration period, 
arteries were treated with 60 mM KCl (<5 min; isosmotic replacement of NaCl with KCl) to test their viabil-
ity. Only arteries with ≥50% constriction in response to 60 mM KCl were used for subsequent experiments. 
Intravascular pressure was increased to 80 mmHg and arteries were allowed to develop myogenic tone. Lumen 
diameters of the adipose arteries were recorded using IonOptix software (IonOptix LLC, Westwood-MA). To 
evaluate the impact of BKCa channels on myogenic tone, arteries were treated with 100 nM Iberiotoxin (IBTx) 
(BKCa channel inhibitor). Percent change in diameter was calculated using the following equation: % myogenic 
tone = [(DP − DA)/DP] × 100, where DP = passive diameter of the artery in Ca2+-free PSS containing the L-type 
Ca2+ channel (LTCC) inhibitor nifedipine (10 μM) and DA = active diameter of the artery in Ca2+-containing 
PSS. Percent constriction in the presence of IBTx or 60 mM K+ was calculated using the following equation: % 
constriction = [(DP − DT)/DP] × 100, where DT = diameter of the artery in Ca2+-containing PSS with 100 nM 
IBTx or 60 mM K+ and DP = passive diameter of the artery in Ca2+-free PSS containing 10 μM of the LTCC 
inhibitor nifedipine.
Electrophysiology. STOCs resulting from the concerted opening of multiple BKCa channels were recorded 
at different membrane potentials from freshly dissociated vascular smooth muscle from small diameter adipose 
arteries using the perforated whole-cell configuration of the patch-clamp technique with an Axopatch 200B 
amplifier (Molecular Devices, Sunnyvale, CA). Currents were sampled at 10 kHz and low-pass filtered at 2 kHz. 
The pipette solution consisted of (in mM): 110 K-aspartate, 30 KCl, 10 NaCl, 1 MgCl2, 0.5 EGTA, and 10 HEPES, 
pH adjusted to 7.3 with KOH. The pipette solution was supplemented with 250 μg/ml of amphotericin B (Sigma, 
St. Louis, MO). Bath solution consisted of (in mM): 130 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 glucose and 10 HEPES, 
pH adjusted to 7.4 with NaOH. STOCs were analyzed using the threshold detection algorithm in Clampfit 10 
(Axon Instruments, Inc).
Single BKCa channel currents were recorded from inside-out membrane patches obtained from freshly disso-
ciated vascular smooth muscle cells from adipose arteries. In some experiments, HEK293 cells expressing either 
the BKCa α subunit and EGFP or co-transfected with BKCa α + β1 subunit in a 1:1 mix and EGFP using PolyPlus 
jetPRIME were used as previously described9. Bath and pipette solutions consisted of (in mM) 140 KCl, 1 HEDTA, 
10 HEPES, pH adjusted to 7.3 with Tris. Bath solution was supplemented with CaCl2 to achieve the desired free Ca2+ 
concentration, as determined with the MaxChelator software. Single-channel currents were amplified, low-pass fil-
tered at 1 kHz, and sampled at 20 kHz with the Axopatch 200B amplifier using a DigiData 1440 A acquisition board 
and pClamp 10 software (Axon Instruments, Inc). Currents were elicited by holding the inside-out patch at the 
specified voltage. Data were directly stored in a PC hard drive. The half-amplitude algorithm of Clampfit 10 was used 
to detect single-channel openings and to analyze data of channel activity (e.g. open probability; Po). The number of 
BKCa channels per patch was estimated by holding the patch at +80 mV in the presence of 10 μM free Ca2+, which 
maximizes the Po of these channels45. Open time histograms were fit using a log-normal function:
= ⋅
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where A is a constant, τ is the time constant, and σ is the standard deviations of τ. This analysis was validated by 
using an Akaike’s Information Criterion, which determines the probability that a data set could be described by a 
particular set of competing models46.
Ca2+ Imaging and Analysis. Freshly dissociated vascular smooth muscle cells from small diameter adipose 
arteries were loaded with the fluorscent Ca2+ indicator fluo-4 AM (5 μM) and imaged using an Andor spinning 
disk confocal microscope system coupled to an Olympus iX81 inverted microscope equipped with a 60x oil 
immersion lens (numerical aperture 1.49). Andor IQ software was used for acquisition. Images were acquired 
at 100–120 Hz. Analysis was performed using custom software (SparkLab) written in LabVIEW that employs a 
computer algorithm as previously described9,47.
Proximity Ligation Assay (PLA). The Duolink in situ PLA detection kit was used to determine colocaliza-
tion between BKCa α and BKCa β1 subunits as previously described40. Freshly dissociated myocytes were plated on 
glass coverslips and allowed to sit for 30 minutes at room temperature. Cells were then fixed in 4% paraformalde-
hyde (20 min) and quenched in 100 mM glycine (15 min), followed by 3 min washes (2x) in a phosphate-buffered 
saline (PBS) solution containing (in mM) 138 NaCl, 3 KCl, 10 Na2HPO4, 2 NaH2PO4, 5 D-glucose, 0.1 CaCl2 and 
0.1 MgSO4, pH adjusted to 7.4 with NaOH. Cells were then permeabilized for 20 minutes in 0.1% Triton-100 
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solution in PBS and blocked in Duolink Blocking Solution for 1 hour at 37 °C in a humidity chamber. Cells were 
incubated overnight with a specific combination of primary antibodies. Mouse anti-BKCa α (Antibodies Inc; 
75–022 1:200) was combined with rabbit anti-BKCa β1 (Abcam; ab3587; 1:200) antibody. As a positive control, 
cells were stained with mouse anti-BKCa α (Antibodies Inc; 75-022 1:200) and rabbit anti-BKCa α (Alamone; APC-
021; 1:200). For negative controls, cells were incubated with only one primary antibody. Antibodies were diluted 
in Duolink Antibody Diluent Solution per manufacturer instructions. Secondary antibodies containing PLA 
probes (anti-mouse minus and anti-rabbit plus) were added to the preparation and allowed to incubate for 1 h 
at 37 °C. A ligation solution consisting of ligase and two distinct oligonucleotides was then added and incubated 
for 30 minutes at 37 °C. This step was followed by an amplification reaction (100 min, 37 °C), and subsequent 
washes (2x) for 10 minutes in Duolink Buffer B and 1 × 1 minute in 1% Buffer B per manufacture’s specifications. 
Coverslips were mounted on a microscope slide with Doulink mounting media. The fluorescence signal was visu-
alized using an Olympus FV1000 confocal system on an Olympus iX81 microscope with a 60X water immersion 
lens (numerical aperture = 1.4). Images were acquired at different optical planes (z-axis step size = 0.5 μm).
Immunofluorescence. Immunofluorescence labeling of freshly dissociated vascular smooth muscle from 
small diameter adipose arteries from non-diabetic and diabetic patients was performed as described previ-
ously10,48 using a rabbit anti-BKCa α (Alamone; APC-021; 1:200) and a rabbit anti-BKCa β1 (Abcam; ab3587; 
1:200). The secondary antibody was an Alexa Fluor 568-conjugated donkey anti-rabbit (5 mg/mL) from Molecular 
Probes. Cells were visualized (512 × 512 pixel images) using an Olympus FV1000 confocal microscope coupled 
with an Olympus X60 water immersion lens (NA = 1.4) and a zoom of 3.5 (pixel size = 0.1 μm). Images were col-
lected at multiple optical planes (z axis step size = 0.25 μm). The specificity of the primary antibody was tested in 
negative control experiments in which the primary antibody was substituted with PBS. Cells for each group were 
imaged using the same laser power, gain settings and pinhole for all treatments.
Western Blot Analysis. Whole tissue homogenates were prepared from dissected adipose arteries. In some 
experiments, protein lysates were obtained from HEK293 cells expressing either the BKCa α or BKCa β1 subunit 
or cells that have not been transfected. Samples were flash frozen in liquid nitrogen and homogenized on ice with 
lysis buffer containing (in mM) 150 NaCl, 10 Na2HPO4, 1 EDTA with 1% deoxycholic acid, 0.1% sodium dodecyl 
sulfate, 40 β-glycerophosphate, 20 Na pyrophosphate, 30 NaF, 1 dithiothreitol and protease inhibitors (Complete 
Mini protease inhibitor cocktail, Roche, San Francisco, CA) in a glass dounce homogenizer. Whole lysates were 
sonicated for 1 min, rested on ice for 20 min, and centrifuged (5000 rpm, 4 °C) to yield clarified supernatant. 
Equal amounts of protein (approximately 10 µg) were separated under reducing conditions on a 4–20% gradi-
ent polyacrylamide gel according to the manufacturer’s specifications (Bio-Rad, Hercules, CA). Proteins were 
transferred to polyvinylidene difluoride (PVDF) or nitrocellulose membranes for Western immunoblotting using 
enhanced chemiluminescence (ECL) and X-ray film or using an Odyssey scanner (LI-COR; Lincoln, NE, USA) 
with far red or near-infrared (NIR) labeled secondary antibodies. For the Odyssey scanner, nitrocellulose mem-
branes were blocked with 50% Odyssey blocking buffer (LI-COR; Lincoln, NE, USA) (40 min) in Tris-buffered 
saline (TBS), then incubated with BKCa subunit specific primary antibodies on a rotating platform for 18–24 h 
(4 °C). Primary antibodies were rabbit anti-BKCa α (Alamone; APC-021; 1:500), rabbit anti-BKCa β1 (Genetex; 
GTX105666; 1:5000; or Abcam; ab3587; 1:500), anti-BKCa γ (Alamone; APC-021; 1:500), and mouse anti-β actin 
(Sigma; AC-40; 1:4000; as a loading control). These antibodies were diluted in TBS with 0.05% tween-20 (t) and 
5% Odyssey blocking solution. Membranes were washed 3 times in TBS-t, then incubated (2 h, room tempera-
ture) with appropriate secondary antibodies: goat anti-rabbit 680LT (LI-COR; 925-68021; 1:15,000; with 0.1% 
SDS), 800CW (LI-COR; 925-32211; 1:15,000; for dual staining) or goat anti-mouse 680LT (LI-COR; 925-68020 
1:10,000) in TBS-t. For the far red or NIR dyes, band images were acquired using an Odyssey scanner. In some 
experiments, detection of BKCa α was acquired by X-ray film. PVDF membranes were blocked with 10% nonfat 
milk for 1 hour, incubated in rabbit rabbit anti-BKCa α (Alomone, 1:500) for 2 hours, washed 3 times in TBS-t, 
incubated in HRP labeled goat anti-mouse (sc-2005; 1:5000; Santa Cruz), then washed 3 times in TBS-t. Bands 
were identified by ECL and exposure to X-ray film, followed by conventional scanning. Densitometry for immu-
noreactive bands was performed with ImageJ software (National Institutes of Health). Band quantification was 
normalized to β actin, and expressed as a percentage of control.
Chemicals and Statistics. All chemical reagents were from Sigma-Aldrich (St. Louis, MO) unless other-
wise stated. Iberiotoxin was from Peptides International (Louisville, KY). Data were analyzed using GraphPad 
Prism software and expressed as mean ± SEM. Data were assessed for potential outliers using the GraphPad 
Prism Outlier Test and for normality of distribution using the Shapiro-Wilk or KS normality tests. Statistical 
significance was then determined using appropriate paired or unpaired Student’s t-test, nonparametric tests or 
One-way analysis of variance (ANOVA) for multiple comparisons with appropriate post hoc test. P < 0.05 was 
considered statistically significant (denoted by * in figures).
Data Availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author in a reasonable request.
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